2025-09-23 - Analysis Report
Okay, here's an analysis of TGTX based on the information you've provided, formatted for clarity and ease of understanding.

**Report: TG Therapeutics Inc (TGTX) Analysis**

TG Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases.

**1. Performance vs. S&P 500 (VOO)**

*   **Cumulative Return:**
    *   TGTX: 67.77%
    *   VOO: 106.97%
    *   Difference: -39.20%
*   **Relative Deviation:** -37.0 (Relative Deviation: 14.4)

    *   *Analysis:* TGTX has underperformed the S&P 500 over the period examined. The relative deviation of 14.4 suggests TGTX is currently near the lower end of its historical performance range relative to VOO.
*   **Alpha, Beta Analysis Table:**

    | Year       | CAGR    | MDD   | Alpha   | Beta   | Cap(B) |
    |------------|---------|-------|---------|--------|--------|
    | 2015-2017  | -6.0%   | 56.5% | -35.0%  | -0.1   | 1.4    |
    | 2016-2018  | -8.0%   | 58.6% | -26.0%  | 0.0    | 0.7    |
    | 2017-2019  | 74.0%   | 58.6% | 44.0%   | 0.0    | 1.9    |
    | 2018-2020  | 402.0%  | 58.6% | 382.0%  | -0.4   | 8.9    |
    | 2019-2021  | 125.0%  | 63.5% | 76.0%   | -0.5   | 3.3    |
    | 2020-2022  | -76.0%  | 70.4% | -78.0%  | -0.6   | 2.0    |
    | 2021-2023  | -350.0% | 70.4% | -368.0% | -0.8   | 2.9    |
    | 2022-2024  | 71.0%   | 73.1% | 45.0%   | -0.9   | 5.2    |
    | 2023-2025  | 75.0%   | 73.1% | 16.0%   | 0.4    | 5.5    |

    *   *Analysis:* The table reveals a mixed performance history.  CAGR fluctuates significantly, with periods of very high growth (e.g., 2018-2020) and substantial losses (e.g., 2021-2023). MDD (Maximum Drawdown) is consistently high, indicating significant risk. Alpha values vary widely, suggesting inconsistent outperformance or underperformance relative to the market. Beta values have fluctuated over time, indicating varying degrees of correlation with the market.

**2. Recent Stock Price Movement**

*   **Current Price:** 32.37
*   **Last Market Data:**
    *   Price: 34.97
    *   Previous Close: 32.37
    *   Change: 8.03% (Significant increase)
*   **Moving Averages:**
    *   5-day: 32.15
    *   20-day: 31.09
    *   60-day: 32.86

    *   *Analysis:* The stock price has experienced a significant increase of 8.03% in the last market session. The 5-day and 20-day moving averages are below the current price, suggesting a short-term upward trend. The 60-day moving average is slightly higher, indicating a potential resistance level.

**3. Risk and Momentum Indicators**

*   **Market Risk Indicator (MRI):** 0.3367 (Low Risk)
*   **RSI:** 75.12 (Overbought)
*   **PPO:** 0.7858
*   **Hybrid Signal:** cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.33)
*   **Delta_Previous_Relative_Divergence (20-day):** -0.1 (Negative - Short-term Decline)
*   **Expected Return (%):** -275.6%

    *   *Analysis:* The MRI indicates a low-risk environment.  However, the RSI is in overbought territory, suggesting the stock may be due for a correction. The significant price change (8.03%) is reflected in the Hybrid Signal. The negative Delta_Previous_Relative_Divergence suggests a recent weakening in relative performance. The very negative expected return suggests significant concerns about long-term outperformance.

**4. Recent News & Significant Events**

*   **[2025-09-22]** Neuraxpharm participates in ECTRIMS.
*   **[2025-09-17]** B. Riley Raises Price Target to $55 (Buy Rating).
*   **[2025-09-12]** Insider Sold Shares Worth $672,268.
*   **[2025-09-10]** Data Presentations for BRIUMVI® in Multiple Sclerosis.
*   **[2025-09-08]** Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment.
*   **[2025-09-07]** $100 Million Buyback Program.

    *   *Analysis:* The news is mixed. Positive catalysts include analyst upgrades, presentations of clinical data, and a share buyback program.  The insider selling is a potential concern.

**4-2. Analyst Opinions**

*   **Consensus:** Buy (Mean: 1.75)
*   **Target Price:**
    *   Average: $40.83
    *   High: $55.00
    *   Low: $11.00

    *   *Analysis:* Analyst consensus is positive with a "Buy" rating.  The average target price suggests potential upside from the current price, but there is a wide range of target prices.

**5. Recent Earnings Analysis**

| 날짜       | EPS   | 매출       |
|------------|-------|------------|
| 2025-08-08 | 0.19  | 0.14 B$    |
| 2025-05-09 | 0.03  | 0.12 B$    |
| 2024-11-07 | 0.03  | 0.08 B$    |
| 2024-08-09 | 0.05  | 0.07 B$    |
| 2025-08-08 | 0.05  | 0.07 B$    |

*   *Analysis:* The most recent EPS (0.19) is significantly higher than previous quarters. Revenue has generally been increasing.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue | Profit Margin |
|--------------|---------|---------------|
| 2025-06-30   | $0.14B  | 86.58%        |
| 2025-03-31   | $0.12B  | 87.14%        |
| 2024-12-31   | $0.11B  | 85.77%        |
| 2024-09-30   | $0.08B  | 88.86%        |
| 2024-06-30   | $0.07B  | 88.70%        |

**Capital and Profitability:**

| Quarter      | Equity  | ROE   |
|--------------|---------|-------|
| 2025-06-30   | $0.28B  | 10.20% |
| 2025-03-31   | $0.24B  | 2.13%  |
| 2024-12-31   | $0.22B  | 10.49% |
| 2024-09-30   | $0.19B  | 2.02%  |
| 2024-06-30   | $0.18B  | 3.87%  |

*   *Analysis:* Revenue is showing a clear upward trend, and profit margins are consistently high. Equity is also increasing, although ROE fluctuates.

**7. Overall Assessment**

TGTX presents a mixed investment picture.

*   **Positives:**
    *   Recent strong earnings and revenue growth.
    *   High profit margins.
    *   Positive analyst ratings and price targets.
    *   Recent positive news flow (clinical trial progress, buyback).
    *   Low Market Risk Indicator (MRI).
*   **Negatives:**
    *   Historical underperformance relative to the S&P 500.
    *   High historical volatility (MDD).
    *   Overbought RSI suggesting a potential short-term pullback.
    *   Insider selling.
    *   Very negative expected return for long-term outperformance.

**Conclusion:**

TGTX appears to be a high-risk, high-reward stock. Recent positive developments and strong earnings growth are encouraging, but investors should be aware of the historical volatility and the potential for a pullback due to the overbought RSI. The very negative long-term expected return is a significant red flag.  Careful consideration of risk tolerance and investment horizon is essential before investing in TGTX.
